Live
FierceBiotech‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC gameClinical OMICsHave Microbubbles Burst Through the Barriers of Genetic Medicine Delivery?AgilentAgilent (A) Has a Consumables-and-Service Analytical Platform Bigger Than a Biotech-Funding Proxy - AlphaStreetClinical OMICsOLE Identified as a Potential Alzheimer’s Therapy Targeting MicrogliaEndpoints NewsFDA gives rejected drugs another chance in post-Makary era10x Genomics Blog10x Genomics (TXG) Launches Cleveland Clinic Partnership For Bladder Cancer Diagnostics - simplywall.stClinical OMICsAI Discovers Two New Antibiotics for Drug-Resistant GonorrheaClinical OMICsGLP-1 Drugs Reduce Crime-Linked BehaviorClinical OMICsMacrophage EGFR Activity Linked to Immune Suppression, Tumor Growth in Colorectal CancerClinical OMICsUnexpected Role for RNA Editing in Cancer Immune Evasion UncoveredClinical OMICsProactive Surveillance Pays Off for Patients with Li-Fraumeni SyndromeClinical OMICsCAR T Success Hinges on Microenvironment Response in GBM
Endpoints News Mar 19, 2026

Collegium is acquiring Corium's approved ADHD drug for $650M

Collegium is acquiring Corium's approved ADHD drug for $650M

Original
Body unavailable. Use the original source.